cardiovascular benefits of glp 1 agonists Bridging the gap between GLP1-receptor and outcomes: evidence for the role tirzepatide | Cardiovascular Diabetology In patients with #obesity, incretin-based
Description
Similarly, Firkins et al
96 Besides, liraglutide treatment prevented the neuroinflammatory process, promoting the production of anti-inflammatory molecules such as IL10, TGF, and arginase 1
Oral formulations are also emerging, which may improve accessibility and further increase uptake
Exenatide has a half-life of 3.34 h, and one dose is seen to be insufficient, so it is taken twice daily
As previously mentioned, patients with T2D on incretin-based therapies showed significant weight loss and improved glycemic control with little experience of hypoglycemia (47)
Kunutsor, S
